Putative neuroprotective pharmacotherapies to target the staged progression of mental illness
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Aim: Neuropsychiatric disorders including depression, bipolar and schizophrenia frequently exhibit a neuroprogressive course from prodrome to chronicity. There are a range of agents exhibiting capacity to attenuate biological mechanisms associated with neuroprogression. This review will update the evidence for putative neuroprotective agents including clinical efficacy, mechanisms of action and limitations in current assessment tools, and identify novel agents with neuroprotective potential. Method: Data for this review were sourced from online databases PUBMED, Embase and Web of Science. Only data published since 2012 were included in this review, no data were excluded based on language or publication origin. Results: Each of the agents reviewed inhibit one or multiple pathways of neuroprogression including: inflammatory gene expression and cytokine release, oxidative and nitrosative stress, mitochondrial dysfunction, neurotrophin dysregulation and apoptotic signalling. Some demonstrate clinical efficacy in preventing neural damage or loss, relapse or cognitive/functional decline. Agents include: the psychotropic medications lithium, second generation antipsychotics and antidepressants; other pharmacological agents such as minocycline, aspirin, cyclooxygenase‐2 inhibitors, statins, ketamine and alpha‐2‐delta ligands; and others such as erythropoietin, oestrogen, leptin, N‐acetylcysteine, curcumin, melatonin and ebselen. Conclusions: Signals of evidence of clinical neuroprotection are evident for a number of candidate agents. Adjunctive use of multiple agents may present a viable avenue to clinical realization of neuroprotection. Definitive prospective studies of neuroprotection with multimodal assessment tools are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683
Brain Volumes in Schizophrenia: A Meta-Analysis in Over 18 000 Subjects
Haijma, S. V., Van Haren, N., Cahn, W., Koolschijn, P. C. M. P., Hulshoff Pol, H. E., & Kahn, R. S. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs118 · Cited by 1,012
Köhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1611 · Cited by 941
Molendijk, M. L., Spinhoven, P., Polak, M., Bus, B. A. A., Penninx, B. W. J. H., & Elzinga, B. M. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.105 · Cited by 702 · cited 2×
“A recent systematic review and meta-analysis of depressed patients (n = 2384 antidepressant-free patients and n = 1249 antidepressant-treated patients) vs healthy controls (n = 2982) suggests antidepressant treatment rectifies deficits in peripheral BDNF (Molendijk et al., 2014); possibly as a secondary result of cent…”
BackgroundGlutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
Kreisel, T., Frank, M. G., Licht, T., Reshef, R., Ben-Menachem-Zidon, O., Baratta, M. V., Maier, S. F., & Yirmiya, R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.155 · Cited by 663
Wise, T., Radua, J., Via, E., Cardoner, N., Abe, O., Adams, T. M., Amico, F., Cheng, Y., Cole, J. H., de Azevedo Marques Périco, C., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.72 · Cited by 606
Fusar-Poli, P., Smieskova, R., Kempton, M. J., Ho, B. C., Andreasen, N. C., & Borgwardt, S. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.06.001 · Cited by 512
Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
Deepmala, Slattery, J., Kumar, N., Delhey, L., Berk, M., Dean, O., Spielholz, C., & Frye, R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.015 · Cited by 463
Self-citationHannon, E., Dempster, E., Viana, J., Burrage, J., Smith, A. R., Macdonald, R., St Clair, D., Mustard, C., Breen, G., Therman, S., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1041-x · Cited by 349 · cited 1×
“This hypothesis was supported in a multicentre epigenome wide analysis of schizophrenic patients vs controls (n = 1714) (Hannon et al., 2016).”
Result
Cited by
Hickie, I. B., Scott, E. M., Cross, S. P., Iorfino, F., Davenport, T. A., Guastella, A. J., Naismith, S. L., Carpenter, J. S., Rohleder, C., Crouse, J. J., et al. (2019) · Medical Journal of Australia · doi:10.5694/mja2.50383 · Cited by 208
The role of mitochondria in mood disorders: from physiology to pathophysiology and to treatment
Giménez-Palomo, A., Dodd, S., Anmella, G., Carvalho, A. F., Scaini, G., Quevedo, J., Pacchiarotti, I., Vieta, E., & Berk, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.546801 · Cited by 140
“It can prevent oxidative damage to complex I (184), can enhance GST activity, and act directly against oxidant radicals (290, 291).”
BackgroundInfluentialNeurodevelopmental pathways in bipolar disorder
Kloiber, S., Rosenblat, J. D., Husain, M. I., Ortiz, A., Berk, M., Quevedo, J., Vieta, E., Maes, M., Birmaher, B., Soares, J. C., et al. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.02.005 · Cited by 122
Self-citationIn vitro effects of antipsychotics on mitochondrial respiration
Cikánková, T., Fišar, Z., Bakhouche, Y., Ľupták, M., & Hroudová, J. (2019) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-019-01665-8 · Cited by 44
Clinical Staging for Youth Mental Disorders: Progress in Reforming Diagnosis and Clinical Care
McGorry, P. D., & Mei, C. (2021) · Annual Review of Developmental Psychology · doi:10.1146/annurev-devpsych-050620-030405 · Cited by 38
Ratajczak, M. Z., Mack, A., Bujko, K., Domingues, A., Pedziwiatr, D., Kucia, M., Ratajczak, J., Ulrich, H., Kucharska-Mazur, J., & Samochowiec, J. (2019) · Stem Cell Reviews and Reports · doi:10.1007/s12015-019-09888-1 · Cited by 32
“Based on clinical and molecular evidence that sterile inflammation of the brain leads to psychotic disorders anti-inflammatory strategies have already been employed in clinical settings [17, 46].”
Metadata
- Authors
- Robertson, O. D., Coronado, N. G., Sethi, R., Berk, M., & Dodd, S.
- Venue
- Early Intervention in Psychiatry
- Publisher
- Wiley
- Published
- 2019-01-28
- Volume
- 13
- Issue
- 5
- Pages
- 1032-1049
- ISSN
- 1751-7885 (ISSN-L)
- 1751-7893
- OpenAlex
- W2911377666
- Cited by
- 52
- References
- 38
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.